Synthesis and preliminary COX-2 expression inhibitory activities of andrographolide derivatives

Letters in Drug Design and Discovery

Volumn 7, Issue 3, 2010, Pages 176-181

  Li, Jing ^a,b   Huang, Wenlong ^b   Zhang, Huibin ^b   Zhou, Huiping ^c  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Andrographolide; COX 2; Derivatives; Expression; Inhibitory activity

Indexed keywords

ANDROGRAPHOLIDE; ANDROGRAPHOLIDE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 77949738094     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010790596614     Document Type: Article

References (24)

1. Willoughby, D.; Moore, A.; Colville-Nash, P. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet, 2000, 355, 646-648.
2. Sugiyama, T.; Yoshimoto, T.; Sato, R.; Fukai, N.; Ozawa, N.; Shichiri, M.; Hirata, Y. Endothelin-1 induces cyclooxygenase-2 expression and generation of reactive oxygen species in endothelial cells. J. Cardiovasc. Pharmacol., 2004, 44, S332-S335.
3. Patel, V.A.; Dunn, M.J.; Sorokin, A. Regulation of MDR-1 (Pglycoprotein) by cyclooxygenase-2. J. Biol. Chem., 2002, 277, 38915-38920.
4. Masferrer, J.L.; Leahy, K.M.; Koki, A.T; Alane, T.; Zweifel, B.S.; Settle, S.L.; Woerner, B.M.; Edwards, D.A.; Flickinger, A.G.; Moore, R.J.; Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 2000, 60, 1306-1311.
5. Tjandrawinata, R.R.; dahiya, R.; Hughes, F.M.; Induction of cyclooxygenase-2 mRNA by prostaglandin E-2 in human prostatic carcinoma cells. Br. J. Cancer., 1997, 75, 1111-1118.
6. Smith, A.B.; Toder, B.H.; Carroll, P.J.; Donohue, J. Andrographolide: an x-ray crystallographic analysis. J. Cryst. Spectrosc. Res., 1982, 12, 309-319.
7. Madav, S.; Tandan, S.K.; Lal, J.; Tripathi, H.C. Anti-inflammatory activity of andrographolide. Fitoterapia, 1996, 67, 452-458.
8. Dai, G.F.; Wang, J.F.; He, S.W.; Xu, H.W.; Lin, L.; Yang, Y.; Liu, H.M. Pharmacological activities of andrographolide and its derivatives. Zhongchengyao, 2006, 28, 1032-1035.
9. Maiti, K.; Gantait, A.; Mukherjee, K.; Saha, B.P. Therapeutic potentials of andrographolide from Andrographis paniculata: a review. J. Nat. Remedies, 2006, 6, 1-13.
10. Fu, S.L.; Lin, C.H.; Lai, J.J.; Sun, C.M. SAR study of the biologically active andrographolide. Huaxue, 2007, 65, 253-271.
11. Habtemariam, S. Andrographolide inhibits the tumour necrosis factor-α-induced upregulation of ICAM-1 expression and endothelial-monocyte adhesion. Phytother. Res., 1998, 12, 37-40.
12. Chiou, W.F.; Chen, C.F.; Lin, J.J. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br. J. Pharmacol., 2000, 129, 1553-1560.
13. Wang, T.G.; Liu, B.; Zhang, W.; Wilson, B.; Hong, J. S. Andrographolide reduces inflammation- mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J. Pharmacol. Exp. Ther., 2004, 308, 975-983.
14. -1): 3436, 3083, 2945, 1837, 1751, 1639, 1448, 1383, 1272, 1091, 1001.
15. -1): 3439, 3083, 2974, 2945, 1747, 1636, 1614, 1441, 1351, 1297, 1088, 1048.
16. -1): 3083, 2938, 2859, 1740, 1643, 1445, 1372, 1236, 1081, 1041.
17. -1): 3083, 2931, 2859, 1733, 1639, 1455, 1380, 1347, 1196, 1077.
18. -1): 3075, 2978, 2937, 2866, 1748, 1720, 1601, 1450, 1270, 1059, 896, 710.
19. -1): 3476, 2931, 2851, 1748, 1708, 1634, 1448, 1308, 1275, 1159, 983, 764.
20. -1): 3480, 3299, 3075, 2960, 2851, 1751, 1744, 1664, 1441, 1351, 1255, 1167, 1089, 1021.
21. -1): 3503, 3090, 2929, 2854, 1748, 1642, 1596, 1453, 1346, 1239, 1104, 1050.
22. Li, J.; Huang, W.L.; Zhang, H.B.; Wang, X.Y.; Zhou, H.P. Synthesis of andrographolide derivatives and their TNF-α and IL-6 expression inhibitory activities. Bioorg. Med. Chem. Lett., 2007, 17, 6891-6894.
23. -1): 3546, 3061, 2927, 2844, 1754, 1741, 1734, 1448, 1351, 1207.
24. Western blot assay: Cells were treated with 20 μM of Andro, its derivatives or vehicle control for 24 h. At the end of the treatment, total cell lysates were prepared. The protein concentration was determined using the Bio-Rad protein assay reagent. The total cellular proteins (10 μg) were resolved on 10 % Bis-Tris gels and transferred to Nitrocellulose membranes. Immunoblots were blocked overnight at 4 ° C with 5 % non-fat milk in TBS buffer and incubated using horseradish peroxidase-conjugated secondary antibody and the Western Lightning Chemiluminescence Reagent Plus. The density of the immunoblot bands was analyzed using Image J computer software (NIH).